Hims & Hers Health (NYSE:HIMS) CFO Sells $275,092.78 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,067 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78. Following the completion of the sale, the chief financial officer owned 91,617 shares in the company, valued at $2,779,659.78. This represents a 9.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.79, for a total value of $306,475.30.
• On Monday, December 22nd, Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.72, for a total value of $824,774.80.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total value of $853,513.47.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total value of $853,513.47.

Hims & Hers Health Price Performance

NYSE HIMS opened at $29.63 on Friday. The company has a 50-day moving average price of $34.95 and a 200-day moving average price of $45.08. Hims & Hers Health, Inc. has a 52 week low of $23.97 and a 52 week high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $6.74 billion, a P/E ratio of 54.86, a PEG ratio of 5.17 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same quarter last year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has approved a share buyback program on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have commented on HIMS shares. Zacks Research cut Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Bank of America increased their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday, November 4th. Barclays assumed coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target on the stock. Evercore ISI assumed coverage on shares of Hims & Hers Health in a research report on Monday, January 12th. They set an “in-line” rating and a $33.00 price objective on the stock. Finally, Leerink Partners raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $44.54.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently made changes to their positions in the company. Quent Capital LLC bought a new position in Hims & Hers Health during the third quarter valued at approximately $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Virtus Advisers LLC purchased a new position in shares of Hims & Hers Health in the second quarter valued at $26,000. Quaker Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the second quarter valued at $29,000. Finally, Bessemer Group Inc. increased its position in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.